Fang Yuan, Gurusamy Kurinchi Selvan, Wang Qin, Davidson Brian R, Lin He, Xie Xiaodong, Wang Chaohua
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD005444. doi: 10.1002/14651858.CD005444.pub3.
Patients with obstructive jaundice have various pathophysiological changes that affect the liver, kidney, heart, and the immune system. There is considerable controversy as to whether temporary relief of biliary obstruction prior to major definitive surgery (pre-operative biliary drainage) is of any benefit to the patient.
To assess the benefits and harms of pre-operative biliary drainage versus no pre-operative biliary drainage (direct surgery) in patients with obstructive jaundice (irrespective of a benign or malignant cause).
We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Clinical Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded until February 2012.
We included all randomised clinical trials comparing biliary drainage followed by surgery versus direct surgery, performed for obstructive jaundice, irrespective of the sample size, language, and publication status.
Two authors independently assessed trials for inclusion and extracted data. We calculated the risk ratio (RR), rate ratio (RaR), or mean difference (MD) with 95% confidence intervals (CI) based on the available patient analyses. We assessed the risk of bias (systematic overestimation of benefit or systematic underestimation of harm) with components of the Cochrane risk of bias tool. We assessed the risk of play of chance (random errors) with trial sequential analysis.
We included six trials with 520 patients comparing pre-operative biliary drainage (265 patients) versus no pre-operative biliary drainage (255 patients). Four trials used percutaneous transhepatic biliary drainage and two trials used endoscopic sphincterotomy and stenting as the method of pre-operative biliary drainage. The risk of bias was high in all trials. The proportion of patients with malignant obstruction varied between 60% and 100%. There was no significant difference in mortality (40/265, weighted proportion 14.9%) in the pre-operative biliary drainage group versus the direct surgery group (34/255, 13.3%) (RR 1.12; 95% CI 0.73 to 1.71; P = 0.60). The overall serious morbidity was higher in the pre-operative biliary drainage group (60 per 100 patients in the pre-operative biliary drainage group versus 26 per 100 patients in the direct surgery group) (RaR 1.66; 95% CI 1.28 to 2.16; P = 0.0002). The proportion of patients who developed serious morbidity was significantly higher in the pre-operative biliary drainage group (75/102, 73.5%) in the pre-operative biliary drainage group versus the direct surgery group (37/94, 37.4%) (P < 0.001). Quality of life was not reported in any of the trials. There was no significant difference in the length of hospital stay (2 trials, 271 patients; MD 4.87 days; 95% CI -1.28 to 11.02; P = 0.12) between the two groups. Trial sequential analysis showed that for mortality only a small proportion of the required information size had been obtained. There seemed to be no significant differences in the subgroup of trials assessing percutaneous compared to endoscopic drainage.
AUTHORS' CONCLUSIONS: There is currently not sufficient evidence to support or refute routine pre-operative biliary drainage for patients with obstructive jaundice. Pre-operative biliary drainage may increase the rate of serious adverse events. So, the safety of routine pre-operative biliary drainage has not been established. Pre-operative biliary drainage should not be used in patients undergoing surgery for obstructive jaundice outside randomised clinical trials.
梗阻性黄疸患者存在多种病理生理变化,会影响肝脏、肾脏、心脏和免疫系统。对于在确定性大手术前进行临时性胆道梗阻缓解(术前胆道引流)是否对患者有益,存在相当大的争议。
评估术前胆道引流与不进行术前胆道引流(直接手术)对梗阻性黄疸患者(无论病因是良性还是恶性)的利弊。
我们检索了Cochrane肝胆组对照试验注册库、Cochrane图书馆中的Cochrane临床对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE和科学引文索引扩展版,检索截至2012年2月。
我们纳入了所有比较梗阻性黄疸患者接受胆道引流后手术与直接手术的随机临床试验,无论样本量、语言和发表状态如何。
两位作者独立评估试验是否纳入并提取数据。我们根据现有患者分析计算了风险比(RR)、率比(RaR)或均值差(MD)及95%置信区间(CI)。我们使用Cochrane偏倚风险工具的组成部分评估偏倚风险(对益处的系统性高估或对危害的系统性低估)。我们通过试验序贯分析评估机遇性影响(随机误差)风险。
我们纳入了6项试验,共520例患者,比较术前胆道引流组(265例患者)与未进行术前胆道引流组(255例患者)。4项试验采用经皮肝穿刺胆道引流,2项试验采用内镜括约肌切开术和支架置入术作为术前胆道引流方法。所有试验中的偏倚风险都很高。恶性梗阻患者的比例在60%至100%之间。术前胆道引流组的死亡率(40/265,加权比例14.9%)与直接手术组(34/255,13.3%)相比无显著差异(RR 1.12;95% CI 0.73至1.71;P = 0.60)。术前胆道引流组的总体严重发病率更高(术前胆道引流组每100例患者中有60例,而直接手术组每100例患者中有26例)(RaR 1.66;95% CI 1.28至2.16;P = 0.0002)。术前胆道引流组发生严重疾病的患者比例显著高于直接手术组(术前胆道引流组75/102,73.5%,直接手术组37/94,37.4%)(P < 0.001)。所有试验均未报告生活质量。两组之间住院时间无显著差异(2项试验,271例患者;MD 4.87天;95% CI -1.28至11.02;P = 0.12)。试验序贯分析表明,对于死亡率,仅获得了所需信息量的一小部分。在评估经皮引流与内镜引流的试验亚组中似乎没有显著差异。
目前没有足够的证据支持或反驳对梗阻性黄疸患者进行常规术前胆道引流。术前胆道引流可能会增加严重不良事件的发生率。因此,常规术前胆道引流的安全性尚未确立。在随机临床试验之外,不应将术前胆道引流用于接受梗阻性黄疸手术的患者。